Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products, and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.
Website: danaher.com



Growth: Bad revenue growth rate -19.1%, there is slowdown compared to average historical growth rates 3.4%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +15.3%

Profitability: LTM EBITDA margin is positive, +23.8%. On average the margin is decreasing unsteadily. Gross margin is high, +60.2%. In the last quarter the company beat the estimated EPS, +4.9%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.4%. Free cash flow yield -0.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 34.2% higher than minimum and 25.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.5x by EV / Sales multiple , the company can be 66.2% overvalued

Insiders: For the last 3 months insiders sold company shares on $26.6 mln (-0.015% of cap.)

Key Financials (Download financials)

Ticker: DHR
Share price, USD:  (+0.6%)248.38
year average price 236.64  


year start price 242.44 2023-05-07

max close price 265.59 2023-09-01

min close price 185.10 2023-10-30

current price 248.38 2024-05-05
Common stocks: 727 076 992

Dividend Yield:  0.4%
FCF Yield LTM: -0.7%
EV / LTM EBITDA: 30.9x
EV / EBITDA annualized: 29.8x
Last revenue growth (y/y):  -19.1%
Last growth of EBITDA (y/y):  -32.5%
Historical revenue growth:  3.4%
Historical growth of EBITDA:  1.1%
EV / Sales: 7.4x
Margin (EBITDA LTM / Revenue): 23.8%
Fundamental value created in LTM:
Market Cap ($m): 180 591
Net Debt ($m): 12 542
EV (Enterprise Value): 193 133
Price to Book: 3.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-01Forbes

The Forgotten Stock Advice That Delivers 170%+ Payout Growth

2024-04-26Forbes

What Should You Do With Danaher Stock At $250 After Q1 Beat?

2024-04-23Zacks Investment Research

Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y

2024-04-23Investors Business Daily

Earnings Today: PulteGroup, Danaher Rally; JetBlue Dives

2024-04-23Zacks Investment Research

Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-04-23Barrons

Danaher Shrugs Off Outlook for Falling Sales

2024-04-23Zacks Investment Research

Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates

2024-04-23Reuters

Danaher beats quarterly estimates on strength in diagnostics business

2024-04-19Zacks Investment Research

Why Danaher (DHR) Might Surprise This Earnings Season

2024-04-18Zacks Investment Research

Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2024-04-23 2024-02-21 2023-10-24 2023-07-25 2023-04-25 2023-02-22 2022-10-20
acceptedDate 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 5 796M 2 693M 6 873M 7 157M 7 167M 8 369M 7 663M
costOfRevenue 2 309M 1 070M 2 873M 3 116M 2 797M 3 430M 3 079M
grossProfit 3 487M 1 623M 4 000M 4 041M 4 370M 4 939M 4 584M
grossProfitRatio 0.602 0.603 0.582 0.565 0.610 0.590 0.598
researchAndDevelopmentExpenses 368M 239M 417M 418M 429M 453M 420M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 807M 766M 2 145M 2 194M 2 147M 2 190M 2 149M
otherExpenses 1 000 000 1 000 000 1 000 000 -29M 2M 0 0
operatingExpenses 2 175M 1 005M 2 562M 2 612M 2 576M 2 643M 2 569M
costAndExpenses 4 484M 2 075M 5 435M 5 728M 5 373M 6 073M 5 648M
interestIncome 60M 117M 79M 59M 48M 29M 9M
interestExpense 65M 78M 73M 67M 68M 64M 42M
depreciationAndAmortization 586M 493M 554M 562M 607M 565M 498M
ebitda 1 898M 1 229M 2 072M 1 459M 2 401M 2 257M 2 513M
ebitdaratio 0.327 0.456 0.301 0.204 0.335 0.270 0.328
operatingIncome 1 312M 541M 1 438M 897M 1 794M 2 261M 2 015M
operatingIncomeRatio 0.226 0.201 0.209 0.125 0.250 0.202 0.263
totalOtherIncomeExpensesNet -41M -200M -47M 495M 4M 501M -84M
incomeBeforeTax 1 271M 457M 1 397M 1 392M 1 798M 2 193M 1 931M
incomeBeforeTaxRatio 0.219 0.170 0.203 0.194 0.251 0.262 0.252
incomeTaxExpense 183M -79M 268M 286M 348M -39M 359M
netIncome 1 088M 1 079M 1 129M 1 106M 1 450M 2 232M 1 572M
netIncomeRatio 0.188 0.401 0.164 0.155 0.202 0.267 0.205
eps 1.470 1.460 1.530 1.500 1.960 3.030 2.130
epsdiluted 1.450 1.450 1.510 1.490 1.940 2.990 2.100
weightedAverageShsOut 741M 740M 739M 737M 729M 729M 729M
weightedAverageShsOutDil 749M 746M 746M 745M 737M 746M 737M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2024-04-23 2024-02-21 2023-10-24 2023-07-25 2023-04-25 2023-02-22 2022-10-20
acceptedDate 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M
netReceivables 3 379M 3 922M 4 201M 4 199M 4 313M 4 918M 4 409M
inventory 2 645M 2 594M 3 024M 3 183M 3 383M 3 110M 3 236M
otherCurrentAssets 1 317M 1 557M 1 703M 1 504M 1 457M 1 860M 1 455M
totalCurrentAssets 14 372M 13 937M 21 205M 17 461M 16 532M 15 883M 14 250M
propertyPlantEquipmentNet 5 662M 4 553M 4 302M 4 176M 4 065M 3 956M 3 719M
goodwill 40 846M 41 608M 39 155M 39 576M 39 856M 39 752M 38 251M
intangibleAssets 19 888M 20 746M 18 786M 19 317M 19 976M 20 300M 19 964M
goodwillAndIntangibleAssets 60 734M 62 354M 57 941M 58 893M 59 832M 60 052M 58 215M
longTermInvestments 370M 5M 4M 0 0 0 0
taxAssets 0 -5M -4M 0 0 0 0
otherNonCurrentAssets 2 264M 3 644M 4 286M 4 372M 4 611M 4 459M 4 846M
totalNonCurrentAssets 69 030M 70 551M 66 529M 67 441M 68 508M 68 467M 66 780M
otherAssets 0 0 0 0 0 0 0
totalAssets 83 402M 84 488M 87 734M 84 902M 85 040M 84 350M 81 030M
accountPayables 1 679M 1 766M 1 894M 1 956M 2 081M 2 296M 2 191M
shortTermDebt 2 846M 1 875M 2 547M 1 590M 1 571M 591M 705M
taxPayables 0 582M 0 0 0 691M 0
deferredRevenue 0 1 465M 0 0 0 1 648M 0
otherCurrentLiabilities 3 253M 3 168M 4 926M 4 858M 5 078M 3 854M 5 106M
totalCurrentLiabilities 7 778M 8 274M 9 367M 8 404M 8 730M 8 389M 8 002M
longTermDebt 16 417M 17 661M 19 513M 18 285M 18 261M 19 086M 18 542M
deferredRevenueNonCurrent 0 249M 0 0 0 235M 0
deferredTaxLiabilitiesNonCurrent 0 4 586M 0 0 0 0 0
otherNonCurrentLiabilities 5 760M 228M 6 439M 6 489M 6 563M 6 550M 23 139M
totalNonCurrentLiabilities 22 177M 22 724M 25 952M 24 774M 24 824M 25 871M 26 035M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 1 100M 1 134M 1 100M 0 0 1 062M 0
totalLiabilities 29 955M 30 998M 35 319M 33 178M 33 554M 34 260M 34 037M
preferredStock 0 0 0 0 1 668M 1 668M 1 668M
commonStock 9M 9M 9M 9M 9M 9M 9M
retainedEarnings 41 962M 41 074M 42 272M 41 344M 40 437M 39 205M 37 177M
accumulatedOtherComprehensiveIncomeLoss -2 744M -1 748M -3 959M -3 576M -2 766M -2 872M -3 854M
othertotalStockholdersEquity 14 215M 14 151M 14 085M 13 939M 12 130M 12 072M 11 985M
totalStockholdersEquity 53 442M 53 486M 52 407M 51 716M 51 478M 50 082M 46 985M
totalEquity 53 447M 53 490M 52 415M 51 724M 51 478M 50 082M 46 985M
totalLiabilitiesAndStockholdersEquity 83 402M 84 488M 87 734M 84 902M 85 040M 84 350M 81 022M
minorityInterest 5M 4M 8M 8M 8M 8M 0
totalLiabilitiesAndTotalEquity 83 402M 84 488M 87 734M 84 902M 85 040M 84 350M 81 022M
totalInvestments 370M 5M 4M 0 0 0 0
totalDebt 19 263M 19 536M 22 060M 19 875M 19 832M 19 677M 19 247M
netDebt 12 232M 13 672M 9 783M 11 300M 12 453M 13 682M 14 097M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2024-04-23 2024-02-21 2023-10-24 2023-07-25 2023-04-25 2023-02-22 2022-10-20
acceptedDate 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 088M 536M 1 129M 1 106M 1 450M 2 232M 1 572M
depreciationAndAmortization 586M 493M 554M 562M 557M 565M 540M
deferredIncomeTax -324M -1 204M 0 0 0 -559M 0
stockBasedCompensation 60M 26M 92M 109M 79M 66M 89M
changeInWorkingCapital -57M -242M -151M 117M -117M -407M -255M
accountsReceivables 516M -387M -56M 134M 631M -343M 11M
inventory -118M 210M 103M 129M -257M 243M -61M
accountsPayables -74M 250M -36M -135M -228M 185M -169M
otherWorkingCapital -381M -315M -162M -11M -263M -492M -36M
otherNonCashItems 970M 2 010M 48M 32M -22M 644M 64M
netCashProvidedByOperatingActivities 1 739M 1 619M 1 672M 1 926M 1 947M 2 541M 2 010M
investmentsInPropertyPlantAndEquipment -291M -402M -365M -341M -275M -329M -277M
acquisitionsNet 0 -5 610M 4M 4M 42M -333M -227M
purchasesOfInvestments -53M -20M -8M -101M -43M -169M -26M
salesMaturitiesOfInvestments 9M 28M 29M 3M 1 000 000 271M 1 000 000
otherInvestingActivites 14M -13M 11M 4M -29M -256M 14M
netCashUsedForInvestingActivites -321M -6 017M -329M -431M -304M -816M -515M
debtRepayment -68M -620M -2 603M 0 -4M -700M 0
commonStockIssued -1 000 000 102M 55M 0 -34M 31M 0
commonStockRepurchased 0 -38M -2 658M 0 38M 46M 0
dividendsPaid -177M -627M -199M -218M -204M -203M -204M
otherFinancingActivites -23M -1 063M 7 848M 10M -58M -80M -26M
netCashUsedProvidedByFinancingActivities -133M -2 246M 2 443M -208M -262M -906M -230M
effectOfForexChangesOnCash -118M 231M -84M -91M 3M 26M -99M
netChangeInCash 1 167M -6 413M 3 702M 1 196M 1 384M 845M 1 166M
cashAtEndOfPeriod 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M
cashAtBeginningOfPeriod 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M 3 984M
operatingCashFlow 1 739M 1 619M 1 672M 1 926M 1 947M 2 541M 2 010M
capitalExpenditure -291M -402M -365M -341M -275M -329M -277M
freeCashFlow 1 448M 1 217M 1 307M 1 585M 1 672M 2 212M 1 733M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-04-23 ET (fiscal 2024 q1)
2023 q4
2024-01-30 ET (fiscal 2023 q4)
2023 q3
2023-10-24 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-04-25 ET (fiscal 2023 q1)
2022 q4
2023-01-24 ET (fiscal 2022 q4)
2022 q3
2022-10-20 ET (fiscal 2022 q3)
2022 q2
2022-07-21 ET (fiscal 2022 q2)
2022 q1
2022-04-21 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-23 10:00 ET
Danaher Reports First Quarter 2024 Results
2024-03-21 20:15 ET
Danaher Schedules First Quarter 2024 Earnings Conference Call
2024-02-27 21:15 ET
Danaher to Present at TD Cowen Health Care Conference
2024-02-22 21:15 ET
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
2024-02-21 21:15 ET
Danaher Announces Quarterly Dividend
2024-02-05 12:30 ET
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
2024-01-30 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2023 Results
2024-01-09 12:30 ET
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
2024-01-08 21:15 ET
Danaher CEO to Comment on Financial Performance
2024-01-02 22:00 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2023-12-21 21:30 ET
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
2023-12-06 12:30 ET
Danaher Completes Acquisition of Abcam
2023-12-05 21:30 ET
Danaher Announces Quarterly Dividend
2023-12-04 21:01 ET
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
2023-11-21 21:15 ET
Danaher to Present at Evercore ISI HealthCONx Conference
2023-11-17 12:00 ET
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
2023-11-06 21:00 ET
Shareholders of Abcam Approve Proposed Acquisition by Danaher
2023-10-31 11:30 ET
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
2023-10-24 10:00 ET
Danaher Reports Third Quarter 2023 Results
2023-10-17 12:15 ET
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
2023-10-12 11:30 ET
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
2023-10-05 12:00 ET
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
2023-09-30 12:00 ET
Danaher Corporation Completes Separation of Veralto Corporation
2023-09-26 20:15 ET
Danaher Schedules Third Quarter 2023 Earnings Conference Call
2023-09-19 11:43 ET
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
2023-09-12 20:30 ET
Danaher Announces Quarterly Dividend
2023-08-31 22:00 ET
Danaher and Veralto to Webcast Investor and Analyst Meeting
2023-08-28 11:35 ET
Danaher to acquire Abcam for $24.00 per Share
2023-08-28 11:30 ET
Danaher to Acquire Abcam
2023-08-25 20:30 ET
Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock
2023-08-16 20:30 ET
Danaher Releases 2023 Sustainability Report
2023-07-25 16:00 ET
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
2023-07-25 15:00 ET
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
2023-07-25 10:00 ET
Danaher Reports Second Quarter 2023 Results
2023-07-17 12:30 ET
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
2023-06-20 21:00 ET
Danaher Schedules Second Quarter 2023 Earnings Conference Call
2023-05-15 06:00 ET
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
2023-05-09 20:30 ET
Danaher Announces Quarterly Dividend
2023-05-03 22:00 ET
Danaher to Present at Bank of America Securities Health Care Conference
2023-05-01 11:32 ET
ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY
2023-04-25 10:00 ET
Danaher Reports First Quarter 2023 Results
2023-04-10 20:30 ET
Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
2023-03-27 20:23 ET
Danaher Schedules First Quarter 2023 Earnings Conference Call
2023-03-07 13:00 ET
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies
2023-02-22 21:30 ET
Danaher Announces Quarterly Dividends
2023-02-08 14:00 ET
Danaher Announces New Environmental and Applied Solutions Company to Be Named Veralto
2023-01-24 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2022 Results
2023-01-09 21:15 ET
Danaher CEO to Comment on Financial Performance
2023-01-03 21:30 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2022-12-27 21:30 ET
Danaher Schedules Fourth Quarter 2022 Earnings Conference Call
2022-12-06 21:20 ET
Danaher Announces Quarterly Dividends
2022-11-22 21:45 ET
Danaher to Present at Evercore ISI HealthCONx Conference
2022-11-15 12:00 ET
Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health Diagnosis in U.S.
2022-11-10 21:15 ET
Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy Innovation
2022-10-20 10:00 ET
Danaher Reports Third Quarter 2022 Results
2022-10-05 20:30 ET
Danaher Releases 2022 Sustainability Report and Announces New Greenhouse Gas Emissions Reduction Target
2022-09-20 20:30 ET
Danaher Schedules Third Quarter 2022 Earnings Conference Call
2022-09-14 20:15 ET
Danaher CEO to Comment on Financial Performance
2022-09-14 20:15 ET
Danaher Announces Intention to Separate Environmental & Applied Solutions Segment to Create an Independent, Publicly Traded Company
2022-09-13 20:15 ET
Danaher Announces Quarterly Dividends
2022-09-01 21:00 ET
Danaher to Webcast Bioprocessing Investor and Analyst Meeting at Cytiva
2022-07-25 11:41 ET
Beckman Coulter Partners with Mass General and BARDA to Identify Severe Pediatric Infections in Emergency Departments
2022-07-21 10:00 ET
Danaher Reports Second Quarter 2022 Results
2022-06-29 21:00 ET
Danaher Announces Appointment of Feroz Dewan to Danaher Board
2022-06-21 20:30 ET
Danaher Schedules Second Quarter 2022 Earnings Conference Call
2022-06-06 16:00 ET
SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022
2022-06-06 16:00 ET
SCIEX Launches the New Cornerstone of Software Ecosystem - SCIEX OS 3.0
2022-05-12 20:30 ET
Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases
2022-05-10 20:15 ET
DANAHER ANNOUNCES QUARTERLY DIVIDENDS
2022-05-09 15:00 ET
RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics
2022-05-04 20:30 ET
Danaher To Present At Bank Of America Securities Health Care Conference
2022-04-21 10:00 ET
Danaher Reports First Quarter 2022 Results
2022-04-12 20:30 ET
Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock
2022-03-28 13:00 ET
Catalytic Data Science Joins Integrated DNA Technologies Align Program
2022-03-21 20:30 ET
Danaher Schedules First Quarter 2022 Earnings Conference Call
2022-03-21 12:55 ET
Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program
2022-03-01 21:30 ET
DANAHER TO PRESENT AT COWEN HEALTHCARE CONFERENCE
2022-02-23 21:15 ET
Danaher Announces Quarterly Dividends
2022-01-27 11:00 ET
Danaher Reports Fourth Quarter And Full Year 2021 Results
2022-01-11 13:00 ET
Pall Corporation's new Supralon™ Filter Element Advances Equipment Protection and Reduces Energy Costs
2022-01-11 11:30 ET
Danaher CEO to Comment on Financial Performance
2022-01-04 21:15 ET
Danaher To Present At J.P. Morgan Healthcare Conference
2021-12-27 21:15 ET
DANAHER SCHEDULES FOURTH QUARTER 2021 EARNINGS CONFERENCE CALL
2021-12-07 21:15 ET
Danaher Announces Quarterly Dividends
2021-12-02 02:15 ET
Danaher Announces Pricing Of Senior Notes Offering
2021-11-30 15:00 ET
IDBS Polar™ Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management
2021-11-29 12:00 ET
Danaher Announces Redemption Of Senior Notes
2021-11-23 21:15 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2021-10-21 10:00 ET
Danaher Reports Third Quarter 2021 Results
2021-10-14 12:10 ET
Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus
2021-10-12 20:30 ET
Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability
2021-09-28 10:00 ET
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%(1) and cutting sample processing time by up to 78%(2)
2021-09-21 20:15 ET
Danaher Schedules Third Quarter 2021 Earnings Conference Call
2021-09-14 20:15 ET
Danaher Announces Quarterly Dividends
2021-09-01 16:14 ET
Demaris Mills Appointed President of IDT
2021-09-01 15:00 ET
SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System
2021-09-01 15:00 ET
SCIEX Builds on Cadence of Innovation in Biopharma With Biologics Explorer
2021-08-30 20:15 ET
Danaher Completes Acquisition of Aldevron
2021-08-25 20:30 ET
Danaher To Webcast Investor And Analyst Meeting
2021-08-24 12:30 ET
Danaher Announces Human Resources And Accounting Leadership Transition Plans
2021-07-27 06:05 ET
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
2021-07-26 12:30 ET
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
2021-07-22 10:00 ET
Danaher Reports Second Quarter 2021 Results
2021-07-01 12:00 ET
Pall Corporation Secures Multi-Million Dollar Contract With Exothera
2021-06-22 20:15 ET
Danaher Schedules Second Quarter 2021 Earnings Conference Call
2021-06-17 15:00 ET
SCIEX Presents New Accurate Mass Instrument, The ZenoTOF 7600 System
2021-06-17 15:00 ET
SCIEX OS Introduces New Software With OneOmics Suite and Molecule Profiler App
2021-06-17 13:00 ET
Danaher To Acquire Aldevron
2021-06-07 20:15 ET
Danaher To Present At Goldman Sachs Global Healthcare Conference
2021-05-27 20:15 ET
Danaher To Present At Jefferies Healthcare Conference
2021-05-13 20:30 ET
Danaher Announces Appointment of A. Shane Sanders to Danaher Board
2021-05-05 20:15 ET
Danaher Announces Quarterly Dividends
2021-05-04 21:45 ET
Danaher To Present At Bank Of America Healthcare Conference
2021-04-26 13:00 ET
Danaher Announces Renowned Scientists To Join New Scientific Advisory Board
2021-04-22 10:00 ET
Danaher Reports First Quarter 2021 Results
2021-04-13 11:00 ET
Danaher Provides Update On First Quarter 2021 Financial Performance
2021-04-01 12:00 ET
Pall Corporation Expands Global Production Capacity
2021-03-25 21:00 ET
Danaher Schedules First Quarter 2021 Earnings Conference Call
2021-03-23 17:53 ET
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
2021-03-18 18:14 ET
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing
2021-03-11 14:00 ET
IDT Acquires Swift Biosciences, a Pioneer in the Development of Next-Generation Sequencing (NGS) Library Preparation Genomics Kits for Academic, Translational, and Clinical Research
2021-03-04 21:15 ET
Danaher To Present At Barclays Global Healthcare Conference
2021-02-23 21:15 ET
Danaher Announces Quarterly Dividends
2021-02-22 21:15 ET
Danaher To Present At Cowen Healthcare Conference
2021-02-01 05:01 ET
Cytiva acquires Vanrx Pharmasystems, Canadian aseptic filling innovator
2021-01-28 11:00 ET
Danaher Reports Fourth Quarter And Full Year 2020 Results
2021-01-25 16:44 ET
Beckman Coulter brings the productivity and efficiency benefits of large volume hematology analyzers to small- and medium-sized labs
2021-01-13 11:59 ET
Danaher CEO To Comment On Financial Performance
2021-01-07 21:15 ET
Danaher Schedules Fourth Quarter 2020 Earnings Conference Call
2021-01-07 21:15 ET
Danaher To Present At J.P. Morgan Healthcare Conference
2020-12-21 21:15 ET
Danaher Announces Executive Appointment
2020-12-16 13:00 ET
Pall Corporation and Single Use Support Partner to Safeguard Storage and Transport Critical Biopharmaceuticals
2020-12-14 13:00 ET
Danaher announces leadership appointment
2020-12-08 21:15 ET
Danaher Announces Quarterly Dividend
2020-11-24 22:00 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2020-11-23 13:00 ET
Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antibody test
2020-11-16 21:15 ET
Danaher To Present At Wolfe Research Healthcare Conference
2020-11-10 21:15 ET
Danaher Releases 2020 Sustainability Report
2020-11-10 08:00 ET
Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries accepting CE Mark and will begin shipping to diagnostics labs
2020-10-27 08:00 ET
Cytiva strengthens support to diagnostics industry with new labs, services and supply chain enhancements
2020-10-22 10:00 ET
Danaher Reports Third Quarter 2020 Results
2020-10-15 12:00 ET
Beckman Coulter receives BARDA funding to validate Monocyte Distribution Width in the rapid detection of Multisystem Inflammatory Syndrome (MIS-C), a severe COVID-19 complication in Children
2020-10-09 12:00 ET
Beckman Coulter SARS-CoV-2 IgM Antibody Test Receives FDA Emergency Use Authorization
2020-10-07 20:15 ET
Danaher Schedules Third Quarter 2020 Earnings Conference Call
2020-10-06 11:00 ET
Danaher Announces Redemption Of Senior Notes
2020-09-30 01:30 ET
Danaher Announces Pricing Of Senior Notes Offering
2020-09-29 11:00 ET
Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV Combination Test
2020-09-25 21:45 ET
Correction Notice To Press Release Regarding Dividend Amount
2020-09-15 20:15 ET
Danaher Announces Quarterly Dividend
2020-09-15 13:00 ET
Beckman Coulter Lauded by Frost & Sullivan for Accelerating Sepsis Detection with the DxH 690T
2020-09-13 19:00 ET
5 years, 500 million USD, and nearly 1,000 people: Cytiva invests for global capacity expansion
2020-09-01 20:15 ET
Danaher Appoints Rainer M. Blair As President And CEO
2020-08-24 12:00 ET
Beckman Coulter Launches SARS-CoV-2 IgM Antibody Test and will begin shipping to U.S. Diagnostics Labs
2020-07-23 12:00 ET
Beckman Coulter's Automated Blood Banking Analyzer Receives 510(k) FDA Clearance
2020-07-23 10:00 ET
Danaher Reports Second Quarter 2020 Results
2020-07-21 20:52 ET
Beckman Coulter Wins SelectScience Awards for Best New Clinical Instrumentation and Customer Service of the Year
2020-07-17 13:15 ET
Beckman Coulter Receives Nine IMV ServiceTrak™ Clinical Laboratory Awards
2020-07-16 11:00 ET
New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs
2020-07-13 20:15 ET
Danaher Schedules Second Quarter 2020 Earnings Conference Call
2020-07-09 15:00 ET
Fully Integrated SCIEX OS Software Launches at Virtual Product Experience
2020-06-09 11:00 ET
Cepheid Announces Development of Four-in-One Combination Test for SARS-CoV-2, Flu A, Flu B and RSV
2020-05-12 20:10 ET
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2020-05-08 05:15 ET
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2020-05-07 12:40 ET
Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock
2020-05-06 20:10 ET
Danaher Corporation Announces CEO Transition
2020-05-06 20:10 ET
Danaher Reports First Quarter 2020 Results
2020-05-05 20:10 ET
Danaher Announces Quarterly Dividend
2020-04-30 13:00 ET
Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition
2020-04-17 10:45 ET
Danaher Corporation Changes Its Annual Shareholders Meeting To A Virtual Format
2020-04-13 10:45 ET
Danaher Provides Update On First Quarter 2020 Financial Performance And Schedules First Quarter Earnings Conference Call
2020-04-03 20:45 ET
Danaher Prices Reopening Of Euro-Denominated Senior Notes
2020-03-31 22:00 ET
Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva
2020-03-26 01:15 ET
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
2020-03-21 13:00 ET
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
2020-03-19 22:50 ET
Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences
2020-02-20 21:15 ET
Danaher Announces Quarterly Dividend
2020-01-30 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2019 Results
2020-01-23 22:30 ET
Danaher Announces Updated Time For Fourth Quarter 2019 Earnings Conference Call
2020-01-13 21:15 ET
Danaher CEO To Comment On Financial Performance
2020-01-07 21:15 ET
Danaher Schedules Fourth Quarter 2019 Earnings Conference Call
2019-12-16 11:00 ET
Danaher Announces Preliminary Results Of Envista Exchange Offer
2019-12-11 21:42 ET
Danaher Announces Final Exchange Ratio Of 5.5784 for Envista Exchange Offer
2019-11-27 21:30 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2019-11-15 11:30 ET
Envista To File Registration Statement In Connection With Danaher Exchange Offer Announcement
2019-11-15 11:30 ET
Danaher Will Commence Exchange Offer Related To Divestiture Of Its Remaining Interest In Envista Through A Split-Off
2019-11-13 21:15 ET
Danaher Announces Appointment of Jessica L. Mega, MD, MPH and Pardis C. Sabeti MD, D.Phil to Danaher Board
2019-10-30 03:01 ET
Danaher Announces Pricing Of Senior Notes Offering
2019-10-28 20:15 ET
Danaher To Present At Baird Global Industrial Conference
2019-10-21 05:00 ET
Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process
2019-03-19 20:15 ET
Danaher Schedules First Quarter 2019 Earnings Conference Call
2019-03-08 21:15 ET
Danaher Announces Quarterly Dividend
2019-03-01 22:00 ET
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2019-02-27 04:15 ET
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering

SEC forms

Show financial reports only

SEC form 10
2024-04-23 00:00 ET
Danaher published news for 2024 q1
SEC form 8
2024-04-22 18:00 ET
Danaher published news for 2024 q1
SEC form 8
2024-04-22 18:00 ET
Danaher published news for 2024 q1
SEC form 10
2024-04-22 17:53 ET
Danaher reported for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Danaher reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 10
2023-10-24 00:00 ET
Danaher published news for 2023 q3
SEC form 8
2023-10-23 17:47 ET
Danaher published news for 2023 q3
SEC form 10
2023-10-23 17:43 ET
Danaher reported for 2023 q3
SEC form 10
2023-07-25 00:00 ET
Danaher published news for 2023 q2
SEC form 8
2023-07-25 00:00 ET
Danaher published news for 2023 q2
SEC form 6
2023-07-24 17:59 ET
Danaher published news for 2023 q2
SEC form 10
2023-07-24 17:46 ET
Danaher reported for 2023 q2
SEC form 6
2023-06-21 17:27 ET
Danaher published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Danaher published news for 2023 q1
SEC form 8
2023-04-25 00:00 ET
Danaher published news for 2023 q1
SEC form 10
2023-04-25 00:00 ET
Danaher published news for 2023 q1
SEC form 10
2023-02-22 16:40 ET
Danaher published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Danaher reported for 2022 q4
SEC form 8
2023-01-24 00:00 ET
Danaher reported for 2022 q4
SEC form 6
2023-01-23 19:58 ET
Danaher published news for 2022 q4
SEC form 6
2023-01-18 17:08 ET
Danaher published news for 2022 q4
SEC form 6
2023-01-09 16:17 ET
Danaher published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Danaher published news for 2022 q4
SEC form 6
2022-12-07 16:58 ET
Danaher published news for 2022 q3
SEC form 10
2022-10-20 00:00 ET
Danaher reported for 2022 q3
SEC form 8
2022-10-20 00:00 ET
Danaher reported for 2022 q3
SEC form 6
2022-10-19 17:58 ET
Danaher published news for 2022 q3
SEC form 10
2022-10-19 17:49 ET
Danaher published news for 2022 q3
SEC form 10
2022-07-21 00:00 ET
Danaher reported for 2022 q2
SEC form 6
2022-07-20 17:49 ET
Danaher published news for 2022 q2
SEC form 10
2022-07-20 17:46 ET
Danaher published news for 2022 q2
SEC form 6
2022-06-29 17:04 ET
Danaher published news for 2022 q1
SEC form 6
2022-06-06 16:59 ET
Danaher published news for 2022 q1
SEC form 6
2022-06-06 16:54 ET
Danaher published news for 2022 q1
SEC form 6
2022-05-12 17:11 ET
Danaher published news for 2022 q1
SEC form 8
2022-04-21 00:00 ET
Danaher reported for 2022 q1
SEC form 10
2022-04-21 00:00 ET
Danaher reported for 2022 q1
SEC form 6
2022-04-20 18:04 ET
Danaher published news for 2022 q1
SEC form 10
2022-04-20 17:52 ET
Danaher published news for 2022 q1
SEC form 6
2022-04-01 07:05 ET
Danaher published news for 2022 q1
SEC form 6
2022-03-30 07:30 ET
Danaher published news for 2021 q4
SEC form 10
2022-02-23 16:49 ET
Danaher published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Danaher published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
Danaher published news for 2021 q4
SEC form 6
2022-01-26 17:46 ET
Danaher published news for 2021 q4
SEC form 6
2022-01-11 07:28 ET
Danaher published news for 2021 q4
SEC form 8
2022-01-11 00:00 ET
Danaher published news for 2021 q4
SEC form 6
2021-12-10 16:36 ET
Danaher published news for 2021 q3
SEC form 6
2021-12-08 17:06 ET
Danaher published news for 2021 q3
SEC form 10
2021-10-21 00:00 ET
Danaher published news for 2021 q3
SEC form 8
2021-10-21 00:00 ET
Danaher published news for 2021 q3
SEC form 6
2021-10-20 18:00 ET
Danaher published news for 2021 q3
SEC form 10
2021-10-20 17:49 ET
Danaher published news for 2021 q3
SEC form 6
2021-09-15 17:13 ET
Danaher published news for 2021 q2
SEC form 6
2021-08-24 16:15 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-26 08:36 ET
Danaher published news for 2021 q2
SEC form 10
2021-07-22 00:00 ET
Danaher published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-21 18:11 ET
Danaher published news for 2021 q2
SEC form 10
2021-07-21 17:58 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-13 17:09 ET
Danaher published news for 2021 q2
SEC form 6
2021-06-11 16:46 ET
Danaher published news for 2021 q1
SEC form 6
2021-06-11 16:41 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-18 17:23 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-18 17:14 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-13 16:38 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-07 08:16 ET
Danaher published news for 2021 q1
SEC form 10
2021-04-22 00:00 ET
Danaher published news for 2021 q1
SEC form 8
2021-04-22 00:00 ET
Danaher published news for 2021 q1
SEC form 6
2021-04-21 18:20 ET
Danaher published news for 2021 q1
SEC form 10
2021-04-21 18:11 ET
Danaher published news for 2021 q1
SEC form 6
2021-04-13 07:12 ET
Danaher published news for 2021 q1
SEC form 6
2021-03-25 07:30 ET
Danaher published news for 2020 q4
SEC form 10
2021-02-24 19:13 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-27 18:19 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-13 07:23 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-05 17:07 ET
Danaher published news for 2020 q4
SEC form 6
2020-10-21 18:28 ET
Danaher published news for 2020 q3
SEC form 10
2020-10-21 18:15 ET
Danaher published news for 2020 q3
SEC form 6
2020-10-06 16:18 ET
Danaher published news for 2020 q3